Notably, anti‐CD47 treatment may enhance anti‐tumor T‐cell immunity [52], and a recent publication on pancreatic cancer indicated that CD47 targeting induces remodeling of tumor‐infiltrating immune cells of the tumor microenvironment [53]. Here, CD47 is linked to familial pancreatic carcinoma.